# Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab

> **NCT01784900** · PHASE2 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 26 (actual)

## Conditions studied

- Patients With Gastric Peritoneal Carcinomatosis

## Interventions

- **DRUG:** Catumaxomab 100µg
- **DRUG:** Catumaxomab 140µg

## Key facts

- **NCT ID:** NCT01784900
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784900, "Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01784900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*